Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis

Narender Nath, Musfiquidin Khan, Manjeet K. Paintlia, MD Nasrul Hoda, Shailendra Giri

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated autoimmune disease of the CNS. Metformin is the most widely used drug for diabetes and mediates its action via activating AMP-activated protein kinase (AMPK). We provide evidence that metformin attenuates the induction of EAE by restricting the infiltration of mononuclear cells into the CNS, down-regulating the expression of proinflammatory cytokines (IFN-γ, TNF-α, IL-6, IL-17, and inducible NO synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES). Furthermore, the AMPK activity and lipids alterations (total phospholipids and in free fatty acids) were restored by metformin treatment in the CNS of treated EAE animals, suggesting the possible involvement of AMPK. Metformin activated AMPK in macrophages and thereby inhibited biosynthesis of phospholipids as well as neutral lipids and also down-regulated the expression of endotoxin (LPS)-induced proinflammatory cytokines and their mediators (iNOS and cyclooxygenase 2). It also attenuated IFN-γ and IL-17-induced iNOS and cyclooxygenase 2 expression in RAW267.4 cells, further supporting its anti-inflammatory property. Metformin inhibited T cell-mediated immune responses including Ag-specific recall responses and production of Th1 or Th17 cytokines, while it induced the generation of IL-10 in spleen cells of treated EAE animals. Altogether these findings reveal that metformin may have a possible therapeutic value for the treatment of multiple sclerosis and other inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)8005-8014
Number of pages10
JournalJournal of Immunology
Volume182
Issue number12
DOIs
StatePublished - Jun 15 2009

Fingerprint

Autoimmune Diseases of the Nervous System
Metformin
Multiple Sclerosis
AMP-Activated Protein Kinases
Autoimmune Experimental Encephalomyelitis
Central Nervous System
Animal Models
Nitric Oxide Synthase
Interleukin-17
Cyclooxygenase 2
Cytokines
Phospholipids
T-Lymphocytes
Lipids
Chemokine CCL5
Matrix Metalloproteinase 9
Cell Adhesion Molecules
Chemokines
Nonesterified Fatty Acids
Endotoxins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. / Nath, Narender; Khan, Musfiquidin; Paintlia, Manjeet K.; Hoda, MD Nasrul; Giri, Shailendra.

In: Journal of Immunology, Vol. 182, No. 12, 15.06.2009, p. 8005-8014.

Research output: Contribution to journalArticle

Nath, Narender ; Khan, Musfiquidin ; Paintlia, Manjeet K. ; Hoda, MD Nasrul ; Giri, Shailendra. / Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. In: Journal of Immunology. 2009 ; Vol. 182, No. 12. pp. 8005-8014.
@article{487ee4a24dae4b7d8347b602ae2bf522,
title = "Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis",
abstract = "Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated autoimmune disease of the CNS. Metformin is the most widely used drug for diabetes and mediates its action via activating AMP-activated protein kinase (AMPK). We provide evidence that metformin attenuates the induction of EAE by restricting the infiltration of mononuclear cells into the CNS, down-regulating the expression of proinflammatory cytokines (IFN-γ, TNF-α, IL-6, IL-17, and inducible NO synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES). Furthermore, the AMPK activity and lipids alterations (total phospholipids and in free fatty acids) were restored by metformin treatment in the CNS of treated EAE animals, suggesting the possible involvement of AMPK. Metformin activated AMPK in macrophages and thereby inhibited biosynthesis of phospholipids as well as neutral lipids and also down-regulated the expression of endotoxin (LPS)-induced proinflammatory cytokines and their mediators (iNOS and cyclooxygenase 2). It also attenuated IFN-γ and IL-17-induced iNOS and cyclooxygenase 2 expression in RAW267.4 cells, further supporting its anti-inflammatory property. Metformin inhibited T cell-mediated immune responses including Ag-specific recall responses and production of Th1 or Th17 cytokines, while it induced the generation of IL-10 in spleen cells of treated EAE animals. Altogether these findings reveal that metformin may have a possible therapeutic value for the treatment of multiple sclerosis and other inflammatory diseases.",
author = "Narender Nath and Musfiquidin Khan and Paintlia, {Manjeet K.} and Hoda, {MD Nasrul} and Shailendra Giri",
year = "2009",
month = "6",
day = "15",
doi = "10.4049/jimmunol.0803563",
language = "English (US)",
volume = "182",
pages = "8005--8014",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis

AU - Nath, Narender

AU - Khan, Musfiquidin

AU - Paintlia, Manjeet K.

AU - Hoda, MD Nasrul

AU - Giri, Shailendra

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated autoimmune disease of the CNS. Metformin is the most widely used drug for diabetes and mediates its action via activating AMP-activated protein kinase (AMPK). We provide evidence that metformin attenuates the induction of EAE by restricting the infiltration of mononuclear cells into the CNS, down-regulating the expression of proinflammatory cytokines (IFN-γ, TNF-α, IL-6, IL-17, and inducible NO synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES). Furthermore, the AMPK activity and lipids alterations (total phospholipids and in free fatty acids) were restored by metformin treatment in the CNS of treated EAE animals, suggesting the possible involvement of AMPK. Metformin activated AMPK in macrophages and thereby inhibited biosynthesis of phospholipids as well as neutral lipids and also down-regulated the expression of endotoxin (LPS)-induced proinflammatory cytokines and their mediators (iNOS and cyclooxygenase 2). It also attenuated IFN-γ and IL-17-induced iNOS and cyclooxygenase 2 expression in RAW267.4 cells, further supporting its anti-inflammatory property. Metformin inhibited T cell-mediated immune responses including Ag-specific recall responses and production of Th1 or Th17 cytokines, while it induced the generation of IL-10 in spleen cells of treated EAE animals. Altogether these findings reveal that metformin may have a possible therapeutic value for the treatment of multiple sclerosis and other inflammatory diseases.

AB - Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated autoimmune disease of the CNS. Metformin is the most widely used drug for diabetes and mediates its action via activating AMP-activated protein kinase (AMPK). We provide evidence that metformin attenuates the induction of EAE by restricting the infiltration of mononuclear cells into the CNS, down-regulating the expression of proinflammatory cytokines (IFN-γ, TNF-α, IL-6, IL-17, and inducible NO synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES). Furthermore, the AMPK activity and lipids alterations (total phospholipids and in free fatty acids) were restored by metformin treatment in the CNS of treated EAE animals, suggesting the possible involvement of AMPK. Metformin activated AMPK in macrophages and thereby inhibited biosynthesis of phospholipids as well as neutral lipids and also down-regulated the expression of endotoxin (LPS)-induced proinflammatory cytokines and their mediators (iNOS and cyclooxygenase 2). It also attenuated IFN-γ and IL-17-induced iNOS and cyclooxygenase 2 expression in RAW267.4 cells, further supporting its anti-inflammatory property. Metformin inhibited T cell-mediated immune responses including Ag-specific recall responses and production of Th1 or Th17 cytokines, while it induced the generation of IL-10 in spleen cells of treated EAE animals. Altogether these findings reveal that metformin may have a possible therapeutic value for the treatment of multiple sclerosis and other inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=67649196932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649196932&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0803563

DO - 10.4049/jimmunol.0803563

M3 - Article

C2 - 19494326

AN - SCOPUS:67649196932

VL - 182

SP - 8005

EP - 8014

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -